Tissue Regenerative Materials - Medical Devices Pipeline Assessment, 2019

Table of Contents

• 1.1 List of Tables 4
• 1.2 List of Figures 5

2 Introduction 6

• 2.1 Tissue Regenerative Materials Overview 6

3 Products under Development 7

• 3.1 Tissue Regenerative Materials - Pipeline Products by Stage of Development 7
• 3.2 Tissue Regenerative Materials - Pipeline Products by Territory 8
• 3.3 Tissue Regenerative Materials - Pipeline Products by Regulatory Path 9
• 3.4 Tissue Regenerative Materials - Pipeline Products by Estimated Approval Date 10

4 Tissue Regenerative Materials - Pipeline Products under Development by Companies 11

• 4.1 Tissue Regenerative Materials Companies - Pipeline Products by Stage of Development 11
• 4.2 Tissue Regenerative Materials - Pipeline Products by Stage of Development 12

5 Tissue Regenerative Materials Companies and Product Overview 13

• 5.1 Biora AB Company Overview 13
  • 5.1.1 Biora AB Pipeline Products & Ongoing Clinical Trials Overview 13
• 5.2 Collagen Matrix Inc Company Overview 14
  • 5.2.1 Collagen Matrix Inc Pipeline Products & Ongoing Clinical Trials Overview 14
• 5.3 Colorado Therapeutics, LLC Company Overview 16
  • 5.3.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 16
• 5.4 credentis AG Company Overview 17
  • 5.4.1 credentis AG Pipeline Products & Ongoing Clinical Trials Overview 17
• 5.5 Gene Techno Science Co Ltd Company Overview 18
  • 5.5.1 Gene Techno Science Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 18

6 Tissue Regenerative Materials- Recent Developments 31

• 6.1 Oct 22, 2019: CollPlant CEO Yehiel Tal appointed to serve on international society for Biofabrication's Industry Relations Committee 31
• 6.2 Sep 26, 2019: CollPlant reports second quarter 2019 financial results and provides business update 31
• 6.3 Aug 29, 2019: Straumann Group announces two appointments to its Executive Management team 33
• 6.4 Aug 14, 2019: Straumann Group: Strong momentum continues as first-half organic revenue climbs 16% and core EBIT margin reaches 28% 34
• 6.5 Jun 20, 2019: Collplant announces corporate name change to Collplant Biotechnologies to better reflect its business 40
• 6.6 Jun 19, 2019: CelGro accelerates dental implant treatment 40
• 6.7 May 30, 2019: CollPlant reports first quarter 2019 financial results and provides business update 42
• 6.8 May 23, 2019: Full availability of Geistlich Fibro-Gide, the alternative soft-tissue graft 44
• 6.9 May 23, 2019: Credentis and DentaQuest Partner to Bring Innovative Cavity Prevention Products to US Markets 45
• 6.10 May 22, 2019: CollPlant Launches New HQ and R&D Center in Israel 46
• 6.11 May 16, 2019: CURODONT REPAIR is the superior treatment for white spots 46
• 6.12 May 01, 2019: Orthocell submits AUS regulatory application for CelGro 46
• 6.13 Apr 30, 2019: Promising start to the year with 17% organic growth in first quarter 47
• 6.14 Apr 11, 2019: CURODONT REPAIR FLUORIDE PLUS - distribution starts in the US 49
• 6.15 Apr 01, 2019: CollPlant Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update 50
• 6.16 Feb 20, 2019: CURODONT PROTECT - Best Prophylaxis during Orthodontic Treatment 52
• 6.17 Feb 19, 2019: Straumann posts strong Q4, lifting full-year organic revenue growth to 19% as underlying EBITDA margin reaches 30% 52
• 6.18 Feb 04, 2019: CollPlant names Jonathan M.N. Rigby as Chairman of the Board 57
• 6.19 Jan 22, 2019: Straumann Group appoints Alastair Robertson as Head of Global People Management & Development 58

7 Appendix 59

• 7.1 Methodology 59
• 7.2 About GlobalData 62
• 7.3 Contact Us 62